• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

上皮间质转化与肿瘤发生中的免疫应答。

Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma.

机构信息

Clinical Researcher, Hospital Ramón y Cajal, 28034 Madrid, Spain.

Department of Pathology, Hospital Ramón y Cajal, 28034 Madrid, Spain.

出版信息

Int J Mol Sci. 2021 Jul 9;22(14):7398. doi: 10.3390/ijms22147398.

DOI:10.3390/ijms22147398
PMID:34299016
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8306902/
Abstract

Metaplastic breast carcinoma (MBC) is a heterogeneous group of infrequent triple negative (TN) invasive carcinomas with poor prognosis. MBCs have a different clinical behavior from other types of triple negative breast cancer (TNBC), being more resistant to standard chemotherapy. MBCs are an example of tumors with activation of epithelial-mesenchymal transition (EMT). The mechanisms involved in EMT could be responsible for the increase in the infiltrative and metastatic capacity of MBCs and resistance to treatments. In addition, a relationship between EMT and the immune response has been seen in these tumors. In this sense, MBC differ from other TN tumors showing a lower number of tumor-infiltrating lymphocytes (TILS) and a higher percentage of tumor cells expressing programmed death-ligand 1 (PD-L1). A better understanding of the relationship between the immune system and EMT could provide new therapeutic approaches in MBC.

摘要

化生性乳腺癌（MBC）是一组罕见的三阴性（TN）浸润性癌，具有不良预后，异质性较大。MBC 的临床行为与其他类型的三阴性乳腺癌（TNBC）不同，对标准化疗更具耐药性。MBC 是上皮-间充质转化（EMT）激活的肿瘤的一个例子。涉及 EMT 的机制可能负责增加 MBC 的浸润和转移能力以及对治疗的耐药性。此外，在这些肿瘤中已经观察到 EMT 与免疫反应之间的关系。在这方面，MBC 与其他 TN 肿瘤不同，表现为浸润性肿瘤的淋巴细胞（TILS）数量较少，表达程序性死亡配体 1（PD-L1）的肿瘤细胞比例较高。更好地了解免疫系统和 EMT 之间的关系可能为 MBC 提供新的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a56b/8306902/09a6593266c8/ijms-22-07398-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a56b/8306902/7d414b6027de/ijms-22-07398-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a56b/8306902/dfda7cab32e8/ijms-22-07398-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a56b/8306902/1308538d61d3/ijms-22-07398-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a56b/8306902/5246ee32b9a3/ijms-22-07398-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a56b/8306902/6b0e45e32f82/ijms-22-07398-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a56b/8306902/09a6593266c8/ijms-22-07398-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a56b/8306902/7d414b6027de/ijms-22-07398-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a56b/8306902/dfda7cab32e8/ijms-22-07398-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a56b/8306902/1308538d61d3/ijms-22-07398-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a56b/8306902/5246ee32b9a3/ijms-22-07398-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a56b/8306902/6b0e45e32f82/ijms-22-07398-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a56b/8306902/09a6593266c8/ijms-22-07398-g006.jpg

相似文献

1
Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma.上皮间质转化与肿瘤发生中的免疫应答。
Int J Mol Sci. 2021 Jul 9;22(14):7398. doi: 10.3390/ijms22147398.
2
Immune parameters associated with survival in metaplastic breast cancer.与化生性乳腺癌生存相关的免疫参数。
Breast Cancer Res. 2020 Aug 18;22(1):92. doi: 10.1186/s13058-020-01330-6.
3
Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.化生性乳腺癌中肿瘤浸润淋巴细胞丰度及程序性死亡配体1表达：对不同化生成分中独特免疫微环境的影响
Virchows Arch. 2021 Apr;478(4):669-678. doi: 10.1007/s00428-020-02954-x. Epub 2020 Oct 21.
4
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).免疫检查点抑制剂的治疗候选物由三阴性乳腺癌（TNBC）中肿瘤浸润淋巴细胞（TILs）和程序性死亡配体 1（PD-L1）表达的状态所阐明。
Breast Cancer. 2018 Jan;25(1):34-42. doi: 10.1007/s12282-017-0781-0. Epub 2017 May 9.
5
Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.影响 PD-L1 免疫检查点疗法治疗乳腺癌疗效的因素：上皮-间充质转化激活的作用
J Immunol Res. 2021 Jan 7;2021:6668573. doi: 10.1155/2021/6668573. eCollection 2021.
6
Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.化生性乳腺癌的综合分析显示程序性死亡配体1频繁过表达。
J Clin Pathol. 2017 Mar;70(3):255-259. doi: 10.1136/jclinpath-2016-203874. Epub 2016 Aug 16.
7
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.肿瘤浸润淋巴细胞、程序性细胞死亡配体-1、CD8 和 FOXP3 在三阴性乳腺癌预后模型中的整合：对 244 例接受标准治疗的 I-III 期患者的分析。
Eur J Cancer. 2020 Sep;136:7-15. doi: 10.1016/j.ejca.2020.05.014. Epub 2020 Jul 1.
8
The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma.程序性细胞死亡蛋白 1 及其配体的预后影响及其与胸腺癌上皮-间充质转化的相关性。
Cancer Med. 2019 Jan;8(1):216-226. doi: 10.1002/cam4.1943. Epub 2019 Jan 1.
9
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.三阴性乳腺癌原发肿瘤与配对淋巴结转移灶中 PD-L1 表达的异质性。
BMC Cancer. 2018 Jan 2;18(1):4. doi: 10.1186/s12885-017-3916-y.
10
Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.利用肿瘤浸润淋巴细胞（TILs）预测乳腺癌患者对艾日布林化疗的治疗反应。
PLoS One. 2017 Feb 6;12(2):e0170634. doi: 10.1371/journal.pone.0170634. eCollection 2017.

引用本文的文献

1
Chemotherapy as a critical treatment modality for non-surgical metaplastic breast cancer: evidence from SEER database and clinical cohort.化疗作为非手术性化生性乳腺癌的关键治疗方式：来自监测、流行病学与最终结果（SEER）数据库及临床队列的证据
Front Oncol. 2025 May 12;15:1534204. doi: 10.3389/fonc.2025.1534204. eCollection 2025.
2
Therapeutic limitations of oncolytic VSVd51-mediated miR-199a-5p delivery in triple negative breast cancer models.溶瘤性水疱性口炎病毒d51介导的miR-199a-5p递送在三阴性乳腺癌模型中的治疗局限性
Sci Rep. 2025 May 13;15(1):16634. doi: 10.1038/s41598-025-01584-0.
3
Metaplastic breast carcinoma: a rare and aggressive entity.

本文引用的文献

1
Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy.针对新辅助化疗后残留三阴性乳腺癌的 mTOR 和 DNA 修复途径。
Sci Rep. 2021 Jan 8;11(1):82. doi: 10.1038/s41598-020-80081-y.
2
Direct and Indirect Regulators of Epithelial-Mesenchymal Transition-Mediated Immunosuppression in Breast Carcinomas.上皮-间充质转化介导的乳腺癌免疫抑制的直接和间接调节因子。
Cancer Discov. 2021 May;11(5):1286-1305. doi: 10.1158/2159-8290.CD-20-0603. Epub 2020 Dec 16.
3
Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance.
化生性乳腺癌：一种罕见且侵袭性强的实体瘤。
Ann Med Surg (Lond). 2025 Jan 9;87(2):985-990. doi: 10.1097/MS9.0000000000002816. eCollection 2025 Feb.
4
Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity.BB-1701的临床前研究，一种具有强大旁观者效应和免疫原性细胞死亡（ICD）活性的靶向HER2的含艾瑞布林的抗体药物偶联物。
Antib Ther. 2024 Jun 25;7(3):221-232. doi: 10.1093/abt/tbae019. eCollection 2024 Jul.
5
Translational Aspects in Metaplastic Breast Carcinoma.化生性乳腺癌的转化研究方面
Cancers (Basel). 2024 Apr 7;16(7):1433. doi: 10.3390/cancers16071433.
6
Drug resistance mechanisms in cancers: Execution of pro-survival strategies.癌症中的耐药机制：促生存策略的实施
J Biomed Res. 2024 Feb 28;38(2):95-121. doi: 10.7555/JBR.37.20230248.
7
Epithelial to mesenchymal transition (EMT) in metaplastic breast cancer and phyllodes breast tumors.上皮间质转化（EMT）在化生性乳腺癌和叶状乳腺肿瘤中的作用。
Med Oncol. 2023 Dec 16;41(1):20. doi: 10.1007/s12032-023-02259-4.
8
PIK3CD correlates with prognosis, epithelial-mesenchymal transition and tumor immune infiltration in breast carcinoma.PIK3CD与乳腺癌的预后、上皮-间质转化及肿瘤免疫浸润相关。
Discov Oncol. 2023 Oct 20;14(1):187. doi: 10.1007/s12672-023-00805-0.
9
Downregulation of ACC expression suppresses cell viability and migration in the malignant progression of breast cancer.ACC表达的下调在乳腺癌的恶性进展中抑制细胞活力和迁移。
Exp Ther Med. 2023 Aug 2;26(3):445. doi: 10.3892/etm.2023.12144. eCollection 2023 Sep.
10
Identification of Bacterial Metabolites Modulating Breast Cancer Cell Proliferation and Epithelial-Mesenchymal Transition.鉴定调节乳腺癌细胞增殖和上皮-间充质转化的细菌代谢物。
Molecules. 2023 Aug 5;28(15):5898. doi: 10.3390/molecules28155898.
γ-分泌酶抑制剂在癌症中的应用：临床疗效的最新观点。
Oncologist. 2021 Apr;26(4):e608-e621. doi: 10.1002/onco.13627. Epub 2021 Jan 2.
4
Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.化生性乳腺癌中肿瘤浸润淋巴细胞丰度及程序性死亡配体1表达：对不同化生成分中独特免疫微环境的影响
Virchows Arch. 2021 Apr;478(4):669-678. doi: 10.1007/s00428-020-02954-x. Epub 2020 Oct 21.
5
Descriptive study of the histopathological subtypes and programmed death-ligand 1 in metaplastic breast carcinoma.描述性研究：化生性乳腺癌的组织病理学亚型和程序性死亡配体 1 表达。
Breast J. 2020 Dec;26(12):2371-2375. doi: 10.1111/tbj.14056. Epub 2020 Sep 22.
6
Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1.多形性乳腺癌常表达免疫检查点标志物 FOXP3 和 PD-L1。
Br J Cancer. 2020 Nov;123(11):1665-1672. doi: 10.1038/s41416-020-01065-3. Epub 2020 Sep 17.
7
Immune parameters associated with survival in metaplastic breast cancer.与化生性乳腺癌生存相关的免疫参数。
Breast Cancer Res. 2020 Aug 18;22(1):92. doi: 10.1186/s13058-020-01330-6.
8
On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?靶向抗转化生长因子-β疗法在临床癌症治疗中未取得成功：尚存哪些挑战？
Front Cell Dev Biol. 2020 Jul 8;8:605. doi: 10.3389/fcell.2020.00605. eCollection 2020.
9
Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma.化生性乳腺癌的分子特征：三阴性乳腺癌的一种罕见亚型
Cancers (Basel). 2020 Jul 8;12(7):1832. doi: 10.3390/cancers12071832.
10
Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance.上皮-间充质转化程序和癌症干细胞表型：乳腺癌治疗耐药性的介导者。
Mol Cancer Res. 2020 Sep;18(9):1257-1270. doi: 10.1158/1541-7786.MCR-20-0067. Epub 2020 Jun 5.